This study investigated the effects of L-carnitine on insulin-like growth factor-I/II (IGF-I/II) and insulin-like growth factor binding proteins (IGFBPs) in streptozotocin (STZ)-induced diabetic rats. Each rat in the three L-carnitine-treated groups was injected subcutaneously with L-carnitine, 50 (D50), 100 (D100), or 200 (D200)mg/kg body weight every other day for four weeks, and animals in normal (N) and diabetic (DM) groups re ceived saline by the same method. Diabetic rats had significantly lower carnitine concentra tions in serum and liver compared with normal rats. Total carnitine concentrations were in creased dose-dependently by carnitine treatment. Total IGF-I in serum from diabetic rats was increased dose-dependently by carnitine treatment, but was statistically significant only in the D200 group. The expression of liver IGF-I mRNA was lower in diabetic rats than in normal rats and increased by L-carnitine treatment. L-Carnitine treatment of diabetic rats had no effect on the levels of IGF-II in serum, liver, and kidney. Although the levels of IGF-II in serum and kidney of diabetic rats were increased in comparison with normal rats. IGF-II mRNA was not expressed in liver. Diabetic rats had markedly lower IGFBP-3 than normal rats did, and IGFBP-3 was increased by L-carnitine treatment. These results demonstrate that L-carnitine treatment of diabetic rats modulates the IGFs/IGFBPs axis. Especially note worthy is that L-carnitine at a dose of 200mg/kg/48h for four weeks was able to restore serum total IGF-I in STZ-induced diabetic rats to nearly normal levels.
Insulin
L-carnitine-treated diabetic rats (data not shown). The patterns of serum IGFBPs analyzed by WLB are shown in Fig. 2 , and 38-42kDa (IGFBP-3), 34kDa (IGFBP-2), and 24kDa (IGFBP-4) were identified. The amount of IGFBP-3 was lower (p<0.05) in diabetic rats than in normal rats, but it increased with L-carnitine treat ment. The amount of IGFBP-2 was decreased in the L -carnitine treated group.
DISCUSSION
This study was conducted to study the effects of Lcarnitine on the levels of IGFs and IGFBPs in STZ-in duced diabetic rats. Several studies reported that poor glycemic control in diabetes is associated with reduced serum IGF-I levels (4, 5). The levels of total and free car nitine in serum are decreased in diabetes, and carnitine deficiency plays an important role in diabetes-related complications (20) .
Our results showed that the levels of serum total IGF-I were increased in parallel with serum total carnitine concentrations induced by subcutaneous injections of L-carnitine.
The main source of circulating IGF-I is considered to be the liver (21) . Increased total IGF-I level in serum may have been due to an increase of IGF-I production in the liver. The area ratios of IGF-I per standard bands were calculated by using area values based on a densi tometric analysis (Fig. 1) . In this study, the levels of IGF-I and the expression of IGF-I mRNA in liver were both increased by L-carnitine treatment. These observations demonstrated that the treatment of STZ-induced dia betic rats with L-carnitine increases hepatic IGF-I mRNA expression, which results in increased IGF-I pro duction in liver and eventually induces increased IGF-I level in serum. However, in contrast to the increased levels of IGF-I in liver, there was a decrease in IGF-I lev els in kidney by treatment with L-carnitine. A typical characteristic of the IGFs/IGFBPs axis in di abetic rats is that IGF-II levels are either increased or unchanged. In our results, IGF-II levels in serum and kidney from diabetic rats were increased in comparison with normal rats, but the IGF-II level in liver was not different between diabetic and normal rats. Also, there was no detectable IGF-II mRNA expression in either normal or diabetic rat liver. It has been reported that IGF-II expression is not continued after birth in rodents, unlike humans (22, 23) . Therefore it can be assumed that the increase of IGF-II in serum from diabetic rat was not due to an increase of IGF-II production in liver. Other tissues may be involved. Recent studies have shown that the renal IGFs/IGFBPs axis is altered in dia betes, suggesting that these changes may be implicated in alterations in renal functions and morphology that accompany diabetes. Because kidney from diabetic rats had a higher IGF-II level than in normal rats, the changes of serum IGF-II level might have been due to an increase in renal synthesis. In this study, we did not determine IGF-II expression in kidney; therefore further work is necessary to determine the relationship be tween IGF-II increase and renal synthesis in diabetes.
The changes in IGFBPs patterns in serum were ana lyzed by WLB. The amount of IGFBP-3 was markedly decreased; however the amount of IGFBP-2 and IGFBP-4 were not changed in serum from STZ-induced dia betic rats in comparison with normal rats. These results were partially explained by the findings of Luo and Murphy (24) , who found a significant increase in the amount of hepatic IGFBP-1. and IGFBP-2 mRNA at one month and three months after the onset of diabetes. In contrast to the increase in hepatic IGFBP-1 and IGFBP-2 mRNA was a significant decrease in hepatic IGFBP-3 mRNA and no significant difference in hepatic IGFBP-4 mRNA levels in diabetic rats. These results may suggest that changes in serum IGFBP-3 in diabetic rats were due to changes in the hepatic IGFBP-3 pattern, and these changes may be regulated at the transcriptional level. The treatment of L-carnitine resulted in a dose-de pendent increase in IGFBP-3, but there were no changes in IGFBP-2 and IGFBP-4. This study is the first to demonstrate an involvement of carnitine with the IGF system. The central role of carnitine on lipid metab olism is well known, but the role of carnitine in carbo hydrate metabolism is less well understood. It has been reported that L-carnitine stimulates the activity of the pyruvate dehydrogenase complex by decreasing the in tramitochondrial acetyl-CoA/CoA ratio through the trapping of acetyl groups. The simultaneous reduction of acetyl-CoA levels in the cytosol further contributes to activate the glycolytic pathway (25) . Recently, De Gaetano et al. (12) demonstrated that increased circu lating carnitine did not alter the insulin sensitivity index or insulin/c-peptide, but glucose disposal from plasma was significantly increased with carnitine in healthy volunteers. They suggested that carnitine might play a role in the therapy of diabetes mellitus. Our results could suggest that L-carnitine treatment of STZ-induced diabetic rats also improved glucose metab olism via modulation of the IGFs and IGFBPs levels. The esterification of long-chain fatty acids to carnitine by CPT-I is an important and possibly rate-limiting step in fatty acid oxidation (26) . The increase in CPT I activity in STZ-induced diabetic rats was expected and is an ef fect seen in various species when fatty acid oxidation is increased (27, 28) . CPT-I activity was not changed by Lcarnitine treatment at the 50mg/kg dose, but it had a tendency to increase at the 100mg/kg dose and was re duced at the 200mg/kg dose (data not shown). If sub sequent research does demonstrate an effect of carni tine supplementation of STZ-induced rats on CPT I ac tivity, that will be an important development deserving further investigation.
In conclusion, these results demonstrate that L-carni tine treatment of STZ-induced diabetic rats modulates the IGFs/IGFBPs axis. It is especially noteworthy that Lcarnitine at a dose of 200mg/kg body weight/48h for four weeks restores serum concentrations of total IGF-I to near normal levels.
